Superficial mycoses in Belgium: Burden, costs and antifungal drugs consumption.
Belgium
antifungal drugs consumption
burden
candidiasis
cost
dermatophytosis
disability-adjusted life years
superficial mycosis
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
20
11
2019
revised:
20
01
2020
accepted:
08
02
2020
pubmed:
13
2
2020
medline:
11
11
2020
entrez:
13
2
2020
Statut:
ppublish
Résumé
Monitoring of superficial mycoses requires more attention due to their important incidence, health costs and antifungal drugs consumption. The objectives were to estimate the burden of superficial mycoses in Belgium and to assess trends in associated antifungal consumption. The burden of dermatophytoses (including onychomycosis), as well as skin and genital candidiasis, was estimated using disability-adjusted life years (DALY). Moreover, trends in systemic and topical antifungal consumption in ambulatory care were examined for the period 2010-2017, together with their associated costs. Due to their high incidence and long treatment duration, dermatophytoses represented the bulk of the burden, accounting for 92.2% of the total DALYs of superficial mycoses. Terbinafine was the most prescribed antifungal in terms of doses (35.4% of the total doses) while fluconazole was the most delivered drug in terms of packages (29.1% of the total packages). More than 70% of the prescriptions were made by general practitioners while consumption varied according to age and gender of the patients. A global 12% decrease in antifungal prescriptions was observed between 2011 and 2017. However, this reduction would result mainly from packaging changes and increased self-medication. A significant decrease in itraconazole treatments was notably compensated by an increased prescription of fluconazole packages. This study emphasises that dermatological presentations of superficial mycoses are the most important in terms of both burden and antifungal consumption in Belgium. Further reduction in antifungals use can be achieved by applying the adequate treatment after identification of the causative agent.
Sections du résumé
BACKGROUND
BACKGROUND
Monitoring of superficial mycoses requires more attention due to their important incidence, health costs and antifungal drugs consumption.
OBJECTIVES
OBJECTIVE
The objectives were to estimate the burden of superficial mycoses in Belgium and to assess trends in associated antifungal consumption.
METHODS
METHODS
The burden of dermatophytoses (including onychomycosis), as well as skin and genital candidiasis, was estimated using disability-adjusted life years (DALY). Moreover, trends in systemic and topical antifungal consumption in ambulatory care were examined for the period 2010-2017, together with their associated costs.
RESULTS
RESULTS
Due to their high incidence and long treatment duration, dermatophytoses represented the bulk of the burden, accounting for 92.2% of the total DALYs of superficial mycoses. Terbinafine was the most prescribed antifungal in terms of doses (35.4% of the total doses) while fluconazole was the most delivered drug in terms of packages (29.1% of the total packages). More than 70% of the prescriptions were made by general practitioners while consumption varied according to age and gender of the patients. A global 12% decrease in antifungal prescriptions was observed between 2011 and 2017. However, this reduction would result mainly from packaging changes and increased self-medication. A significant decrease in itraconazole treatments was notably compensated by an increased prescription of fluconazole packages.
CONCLUSION
CONCLUSIONS
This study emphasises that dermatological presentations of superficial mycoses are the most important in terms of both burden and antifungal consumption in Belgium. Further reduction in antifungals use can be achieved by applying the adequate treatment after identification of the causative agent.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-508Subventions
Organisme : Sciensano
Informations de copyright
© 2020 Blackwell Verlag GmbH.
Références
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases - estimate precision. J Fungi. 2017;3:57.
Drgona L, Khachatryan A, Stephens J, et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 2014;33:7-21.
Vallabhaneni S, Mody RK, Walker T, et al. The global burden of fungal diseases. Infect Dis Clin N Am. 2016;30:1-11.
Goemaere B, Lagrou K, Spriet I, et al. Systemic antifungal drug use in Belgium - one of the biggest antifungal consumers in Europe. Mycoses. 2019;62:542-550.
Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European surveillance of antimicrobial consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother. 2010;65:769-774.
Adriaenssens N, Coenen S, Versporten A, Goossens H. Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insight. Int J Antimicrob Agents. 2013;42:466-470.
Goossens H, Coenen S, Costers M, et al. Achievements of the Belgian antibiotic policy coordination committee (BAPCOC). Euro Surveill. 2018;13(46):19036.
James SL on behalf of the GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-1858.
Devleesschauwer B, Maertens de Noordhout C, Smit GSA, et al. Quantifying burden of disease to support public health policy in Belgium: opportunities and constraints. BMC Public Health. 2014;14:1196.
Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Public Health. 2014;59:565-569.
Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3:e712-e723.
Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961-1971.
Evans EC, Gray M. What interventions are effective for the prevention and treatment of cutaneous candidiasis? J Wound Ostomy Continence Nurs. 2003;30:11-16.
Ely JW, Rosenfeld S, Seabury SM. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90:702-711.
Ghannoum M, Isham N. Fungal nail infections (onychomycosis): a never-ending story? PLoS Pathog. 2014;10:e1004105.
Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicentre Canadian survey of 15000 patients. J Am Acad Dermatol. 2000;43:244-248.
Aguin TJ, Sobel JD. Vulvovaginal candidiasis in pregnancy. Curr Infect Dis Rep. 2015;17:30.
Odds FC, ed. Candida and Candidosis, 2nd edn. London: Baillière Tindal; 1988.
Lagrou K, Maertens J, Van Even E, Denning DW. Burden of serious fungal infections in Belgium. Mycoses. 2015;58:1-5.
Foxman B, Muraglia R, Dietz J-P, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17:340-345.
Martinez-Rossi NM, Bitencourt TA, Peres NTA, et al. Dermatophyte resistance to antifungal drugs: mechanisms and prospectus. Front Microbiol. 2018;9:1108.
Santos HL, Lang EAS, Segato F, Rossi A, Martinez-Rossi NM. Terbinafine resistance conferred by multiple copies of the salicylate 1-monooxygenase gene in Trichophyton rubrum. Med Mycol. 2018;56:378-381.
Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitle isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477-484.
Yamada T, Maeda M, Alshahni MM, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61:e00115-17.
Yadgar RJ, Bhatia N, Friedman A. Cutaneous fungal infections are commonly misdiagnosed: a survey-based study. J Am Acad Dermatol. 2017;76:562-563.